Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: Results from an independent study
Citations Over TimeTop 13% of 2017 papers
Abstract
Abstract Patients with myelofibrosis at intermediate‐1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate‐2/high International Prognostic Score System risk, safety and efficacy data in intermediate‐1 patients are limited. We report on 70 intermediate‐1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG‐MRT criteria. At 6 months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3 months, ruxolitinib‐induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most (82.6%) patients were still on therapy after a median follow‐up of 27 months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects.
Related Papers
- → Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial(2015)99 cited
- → Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series(2018)29 cited
- → Ruxolitinib for the Treatment of Disease-Related Splenomegaly or Symptoms in Adult Patients with Myelofibrosis(2014)1 cited
- → Significant Improvement in Quality of Life (QoL) in Patients With Chronic Myeloproliferative Neoplasms (CMPN) and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib(2014)
- → Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico(2013)